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Background: There are no vaccines against paratyphoid fever in clinical use. The disease has become
more wide-spread and there is a growing problem of antibiotic resistance among the strains. Previous
reports suggest that the oral live Salmonella Typhi Ty21a-vaccine confers protection against paratyphoid
B fever. Data on efﬁcacy against paratyphoid A fever are somewhat contentious. The present study inves-
tigated the immunological basis for such efﬁcacy reports at a single-cell level: plasmablasts (identiﬁed
as antibody-secreting cells, ASC) were studied for secretion of antibodies cross-reactive with Salmonella
Paratyphi in the circulation of patients with enteric fever and of volunteers vaccinated with Ty21a.
Materials andmethods: Thirty volunteers immunizedwith Ty21a and ﬁve patientswith enteric feverwere
investigated for Salmonella Typhi and Salmonella Paratyphi A/B/C-speciﬁc circulating plasmablasts. PBMC
were sorted by their expression of homing receptors (HR) for the intestine (47), peripheral lymphnode
(l-selectin) and skin (CLA) and typhoid- and paratyphoid-speciﬁc plasmablasts were enumerated with
ELISPOT.
Results: Before vaccination, no cross-reactive ASC were found in the volunteers. In addition to the
Salmonella Typhi-speciﬁc response, a signiﬁcant cross-reactive immune response was mounted against
Salmonella Paratyphi A and B both in the patients and the vaccinees. The magnitude of the response
increased in the order Salmonella Paratyphi A (median 30 ASC/106 PBMC)→ Salmonella Paratyphi B
(median 81)→ Salmonella Typhi (median 301) in the vaccinees. Both in patients and in vaccinees, the
homing receptor (HR) selection favored homing to the gut, indicating a humoral intestinal immune
response.
Conclusions: These immunological data provide evidence consistentwith previous reports describing cer-
tain levels of cross-protective efﬁcacy of Ty21a against paratyphoid fever. Controlled studies are needed
to evaluate cross-protective efﬁcacy. In the current situation where paratyphoid fever is emerging and
no vaccines are available, any level of cross-protective capacity is valuable.. Introduction
Paratyphoid fever, causedby Salmonella enterica serovar Paraty-
hi A and B (Salmonella Paratyphi A and B) and, albeit rarely,
almonella enterica serovar Paratyphi C (Salmonella Paratyphi C),
s a systemic disease with clinical features indistinguishable from
Abbreviations: ASC, antibody-secreting cell; CLA, cutaneous lymphocyte anti-
en; HR, homing receptor; PBMC, peripheral blood mononuclear cell.
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typhoid fever [1–6]. Globally, it has been estimated that there
are 5.4 million cases of paratyphoid fever annually [6], with
incidence on the increase both in endemic areas [5,7–10] and
among travelers [5,10,11]. The major burden of enteric fever (both
typhoid and paratyphoid fever) is in Africa, Asia, and Latin Amer-
ica [6,12,13], with the highest incidence in the Indian subcontinent
and in South-East Asia [6,12–14]. As with Salmonella Typhi, there is
serious concern about increasing antimicrobial resistance among
Salmonella Paratyphi strains [5,10,12,13,15,16], underscoring the
urgent need for vaccines. However, as opposed to Salmonella Typhi,
there are currently no vaccines targeted against Salmonella Paraty-
phi in clinical use.
By revisiting old data from ﬁeld trials on typhoid vaccination
in Chile, Levine et al. showed that the oral live Salmonella Typhi
Ty21a vaccine (Ty21a), while conferring protection against typhoid
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ever, also conferred cross-protection against paratyphoid fever
aused by Salmonella Paratyphi B [17]. In line with this, studies
y Meltzer et al. have suggested that in contrast to the parenteral
i-capsular polysaccharide vaccine, Ty21a may  confer some cross-
rotection against Salmonella Paratyphi A [3]. Similar results have
een obtained in some other studies [18], while others have failed
o conﬁrm this [19]. Controlled studies are needed to establish the
ross-protective efﬁcacy.
As  Salmonella Paratyphi is transmitted by ingestion of con-
aminated food or water, an effective intestinal immune response
ould serve as a ﬁrst line of defense. The immune response
o Ty21a has been shown to consist of both mucosal and sys-
emic humoral and cell-mediated immune responses [20–26]. The
ntestinal immune response has been characterized [20,27–32]
ith the help of gut-derived plasmablasts. These cells are recircu-
ating intestinal lymphocytes which have become activated upon
ntigen encounter, migrated to local lymph nodes and are on their
ay back to the intestine via lymphatics and blood [33–35]. Catch-
ng these cells from circulation before they home back to the
ntestine has been used to study intestinal immune response both
o oral vaccines [20] and in enteric infections [36–38]. The lym-
hocytes all carry the HR 47 [29,37], known to guide cells from
he circulation into the intestinal lamina propria [33–35,39]. Prior
o this, the approach of examining gut-originating recirculating
ells has not been exploited to evaluate cross-reactive immune
esponses.
Previous reports on the cross-protective capacity of Ty21a
gainst paratyphoid fever appear promising as there are no
accines available against paratyphoid fever. To examine the the-
retical grounds for these reports, we investigated immunological
vidence of a cross-reactive Salmonella Paratyphi-speciﬁc intesti-
al antibody response in enteric fever and after ingestion of the oral
y21a (Vivotif®) vaccine. Any level of cross-protective capacity in
 currently available vaccine warrants further exploration.
.  Material and methods
Plasmablasts,  identiﬁed as ASC in samples of peripheral
lood, were examined for their production of antibodies against
almonella Typhi, Salmonella Paratyphi A, B, C and Salmonella Egusi
n patients with enteric fever and in volunteers vaccinated with
y21a.
.1. Volunteers, vaccinations and samples
The study protocol was approved by the ethics commit-
ee of the Helsinki University Central Hospital and the Finnish
edicines Agency. The study protocol was registered in the Inter-
ational Standard Randomised Controlled Trial Number Register
ISRCTN68125331). Written informed consent was obtained from
ll study subjects. The patients enrolled in this study were treated
n the Division of Infectious Diseases, Helsinki University Central
ospital.
Thirty healthy Finnish born volunteers (18 females, 12 males,
ged 18–62 years, mean age 32 years), four patients with typhoid
ever (two females, two males, aged 22–29 years) and one with
aratyphoid fever (female, 30 years) were enrolled. Of the patients
ith typhoid fever, two were Finnish born travelers to India and
outh-America, one was an applicant for asylum from Sri Lanka
nd one was an immigrant from Nepal who had visited relatives in
is home country. The last patient was having an infection relapse
ne month after the ﬁrst episode. The patient with paratyphoid A
ever was an immigrant from India who had visited relatives in her
ome country. Typhoid and paratyphoid fever were diagnosed on
he basis of blood cultures. 30 (2012) 6047– 6053
None of the vaccinees had a previous history of receiving typhoid
vaccine or having enteric fever. They were given the oral Salmonella
Typhi Ty21a vaccine containing ≥2 × 109 live bacteria/capsule
(Vivotif®, Crucell, Leiden, The Netherlands, lot 3001777) admin-
istered one capsule per day on days 0, 2 and 4, as recommended
by the manufacturer. Peripheral venous blood was drawn on days
0 and 7 after vaccination or 7–10 days after the onset of symptoms
of the infection.
2.2.  Antigen
To  include as many antigenic structures as possible, whole bac-
teria of strains Salmonella Typhi (Vsa61), Salmonella Paratyphi A
(RHS6716), B (RHS6744), C (ATCC-13428) and Salmonella Egusi
(RHS6854) were used as antigens in the ELISPOT assay. Salmonella
Paratyphi C strain was from the American Type Culture Collec-
tion (ATCC, Manassas, VA, USA), while the other strains were from
the National Institute for Health and Welfare, Helsinki, Finland.
Bacteria were cultured on nutrient agar plates to determine their
concentration in the suspension, and formalin-killed as described
previously [20]. For ELISPOT assays, the concentration was adjusted
to 109 bacteria/ml in PBS (phosphate buffered saline).
2.3.  Isolation of peripheral blood mononuclear cells
PBMC were separated using Ficoll-plaque density gradient cen-
trifugation as described previously [20].
2.4. Separation of the receptor-negative and -positive cell
populations
The  analyses of HR expressions were carried out for 15 vac-
cinees and for the four patients with enteric fever as a primary
infection. Only one strain per person could be analyzed because
of limited numbers of PBMC. Salmonella Paratyphi B (6 volunteers)
was chosen for determinations as it yielded highest ASC numbers
in preliminary experiments. For comparison, determinations with
Salmonella Typhi were made (9 volunteers). Separation of the cells
into HR-positive and -negative populations has been described ear-
lier [29,37,40]. Brieﬂy, aliquots of cell suspensions were incubated
with monoclonal antibodies to 47 (ACT-1, Millennium Phar-
maceuticals, Cambridge, MA), l-selectin (Leu-8, Becton Dickinson,
Erenbodegem-Aalst, Belgium) or cutaneous lymphocyte antigen
(CLA) (HECA-452; received from Sirpa Jalkanen, Finland, originat-
ing from Eugene Butcher, California), washed three times, and
incubated with Dynal® M-450 magnetic beads coated with sheep
anti-mouse IgG (Dynabeads, Dynal Biotech, Oslo, Norway), fol-
lowed by magnetic separation. Separated cells were immediately
studied with the ELISPOT assay.
2.5. ELISPOT assay
The  receptor-positive and -negative cell populations were
assayed for antigen-speciﬁc ASC using ELISPOT as described
previously [20]. In brief, 96-well microtiter plates (Maxisorp,
Nunc, Roskilde, Denmark) were coated with a preparation of
formalin-killed bacteria. The cells were incubated in the wells
for 2 h, and antibodies detected with alkaline phosphatase-
conjugated goat anti-human IgA (Sigma–Aldrich, MO,  USA), IgG
(Sigma–Aldrich) and IgM (SouthernBiotech, Birmingham, England).
The substrate (bromo-4-chloro-3-indolyl phosphate p-toluidine
salt; Sigma–Aldrich) was added in melted agarose. Each spot enu-
merated under a light microscope was interpreted as a print of one
ASC.
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F or C or Salmonella Egusi)-speciﬁc plasmablasts (pre-plasma cells), identiﬁed as antibody-
s ots represent results of individual vaccinees and the lines the medians of the numbers of
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Fig. 2. Immunoglobulin isotype distribution of antibodies secreted by Salmonella
Typhi,  Salmonella Paratyphi A and B-speciﬁc plasmablasts (ASC)/106 PBMC in 30
volunteers immunized with the Salmonella Typhi Ty21a vaccine. The dots representig. 1. Numbers of circulating antigen (Salmonella Typhi, Salmonella Paratyphi A, B 
ecreting cells (ASC) in 30 volunteers vaccinated with the oral Ty21a vaccine. The d
g(A  + G + M)-plasmablasts on day 0 and 7 after vaccination. (LOD = limit of detectio
.6. Statistics
ASC were characterized using medians and ranges. The dis-
ribution of the data was tested with Shapiro–Wilk’s test, which
howed that the data were not normally distributed. The differ-
nces between groups were tested using Mann–Whitney U-test and
onferroni’s method was used to correct the p-values. Differences
ere considered signiﬁcant when p < 0.05. Statistical analyses were
arried out using SAS for Windows, Version 9.2 (SAS Institute Inc.,
ary, NC, USA).
The  proportions of the receptor-positive ASC were calculated
rom (number of ASC in receptor-positive population)/(sum of the
umber of ASC in receptor-positive and -negative populations), and
xpressed as a percentages ±SD. In order to obtain reliable percent-
ges, only measurements with ≥20 ASC were included in the HR
nalyses.
. Results
.1. ASC response in vaccinees
No  Salmonella Paratyphi A/B/C- or Salmonella Egusi-speciﬁc ASC
ere found in the circulation of any of the vaccinees before vaccina-
ion (Fig. 1); one volunteer had 5 Salmonella Typhi-speciﬁc ASC/106
BMC before vaccination. Seven days after vaccination Salmonella
yphi-speciﬁc ASC were detected in 30/30 vaccinees (Fig. 1) and
almonella Paratyphi A- and B-speciﬁc ASC in 28/30 vaccinees;
/30 vaccinees had a minor response to Salmonella Paratyphi C and
one to Salmonella Egusi (Fig. 1). The medians of the numbers of
athogen-speciﬁc ASC and the statistical comparisons are indicated
n Table 1. The isotype distributions are indicated in Fig. 2..2.  ASC response in patients with enteric fever
All patients with typhoid fever had ASC speciﬁc to Salmonella
yphi, Salmonella Paratyphi A, B and C, while none had ASC speciﬁcresults  of individual vaccinees and the lines the medians of the numbers of plas-
mablasts  secreting speciﬁc antibodies of the IgA, IgG or IgM isotype on day 7 after
vaccination.
to Salmonella Egusi. In patients with primary infection, the median
(min–max) of the number (/106 PBMC) of ASC (IgA + IgG + IgM) was
241 (175–613) for those speciﬁc to Salmonella Typhi, 85 (32–225) to
Paratyphi A, 30 (24–133) to Paratyphi B and 8 (6–10) to Paratyphi C
(Fig. 3A). In the patient with the relapse, the numbers of ASC were
28, 14, 28 and 4/106 PBMC, respectively (Fig. 3 B). In the patient
with a Salmonella Paratyphi A infection, the respective numbers
were 13, 23, 19 and 0/106 PBMC, with no response to Salmonella
Egusi (Fig. 3C).
3.3.  The expression of l-selectin, ˛4ˇ7 and CLA
The  expressions of HR (mean ± SD) on Salmonella Typhi – and
Salmonella Paratyphi B-speciﬁc ASC in the vaccinees are shown in
Fig. 4. Almost all of the ASC expressed the intestinal HR, 47-
integrin (95 ± 5% to Salmonella Typhi and 97 ± 6% to Salmonella
Paratyphi B), while the peripheral lymph node HR, l-selectin, and
the cutaneous HR, CLA, were found on smaller proportions of them
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Table  1
Numbers of antigen (Salmonella Typhi, Salmonella Paratyphi A, B, C or Salmonella Egusi)-speciﬁc plasmablasts (ASC) in 30 volunteers on day 7 after Ty21a vaccination (medians
and  minimum and maximum values) and statistical comparison between cross-reactive responses to various antigens. The statistical comparisons (Mann–Whitney U with
Bonferroni correction) between the Salmonella strains are indicated with asterisks (***p < 0.001; **0.001 < p < 0.01; *0.01 < p < 0.05).
Salmonella enterica serotype ASC Comparison with Salmonella enterica serotype
Median Min–Max Typhi Paratyphi A Paratyphi B Paratyphi C Egusi
Typhi 308 15–1845 – *** * *** ***
Paratyphi  A 30  0–561 *** – NS *** ***
Paratyphi  B 81 0–1449 * NS – *** ***
Paratyphi  C 0 0–20 *** 
Egusi  0 0–3 *** 
Fig. 3. Numbers of circulating antigen (Salmonella Typhi, Salmonella Paratyphi A,
B, C or Salmonella Egusi)-speciﬁc plasmablasts (ASC) in three patients with typhoid
fever in Panel A, one patient with relapsing typhoid fever in Panel B and one patient
with  paratyphoid A fever in Panel C. The dots represent the individual numbers of
IgA, IgG, IgM, Ig(A + G + M)  ASC/106 PBMC on days 7–10 after the onset of symptoms
of  the infection.
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against paratyphoid B fever. The numbers of paratyphoid A cases
were too low to allow an analysis of efﬁcacy against this pathogen.
The immunological background accounting for the cross-
protection elicited by Ty21a against paratyphoid fever has been27 ± 17% and 0.4 ± 1% to Salmonella Typhi and 49 ± 18% and 7 ± 8%
o Salmonella Paratyphi B, respectively).
The expressions of HR on pathogen-speciﬁc ASC in patients with
nteric fever are shown in Fig. 4. Almost all ASC expressed 47-
ntegrin (92 ± 7%), while l-selectin and CLA were expressed less
requently (50 ± 25% and 8 ± 10%), thus resembling the HR-proﬁle
f the Salmonella Typhi- and Paratyphi B-speciﬁc responses in vac-
inees in this and previous studies [18,31].*** *** – NS
*** *** NS –
4.  Discussion
There are no vaccines against paratyphoid fever in clinical use.
This study presents immunological evidence supporting studies
that have previously reported the potential of Ty21a vaccine to
protect against paratyphoid fever.
There are four studies evaluating the protective efﬁcacy of either
Ty21a or the old parenteral whole cell vaccine (no longer in use)
against Salmonella Paratyphi A. Two  of these report protection
[3,18] and two  of them do not [19,41]. In a study in travelers to
Nepal, the majority of those immunized with a whole-cell par-
enteral vaccine and some with Ty21a, Schwartz et al. estimated an
overall efﬁcacy of 95% against Salmonella Typhi and 72–75% against
Salmonella Paratyphi A [18]. Meltzer et al. evaluated imported cases
of enteric fever in Israeli travelers to India in an observational study.
Travellers were immunized with Ty21a until 2001 and after that
with parenteral Vi-polysaccharide vaccine. The general attack rate
by Salmonella Paratyphi A was  0.26 in 10,000 during Ty21a and
0.79 during Vi-vaccination. Thus, Ty21a was suggested to confer
some protection against Salmonella Paratyphi A [3]. In contrast to
these studies, in a large ﬁeld trial in Plaju, Indonesia, Ty21a was not
found to protect against paratyphoid A [19]. However, in that study
three doses of Ty21a were administered at an interval of seven
instead of two  days between doses, leading also to a poor pro-
tective efﬁcacy of only 42% against typhoid fever. The seven-day
interval between doses does not correspond to the most effec-
tive and licensed day 0, 2, 4 immunization schedule and therefore
might be too long. Intestinal immunity is elicited within a week
and previous doses in this schedule may  act against the last two
doses, as shown in studies focusing on dosing intervals of Ty21a
[27,28]. Hence, it could be argued that only one effective dose
was administered in that study. The lack of cross-protection has
also been suggested to be due to a particularly high incidence
of the disease at that trial venue [17]: protection provided by
inactivated whole-cell parenteral typhoid vaccines can be insufﬁ-
cient if the challenge inoculum is high enough [42]. In Thailand,
Bodhidatta et al. [41] reported a decrease in Salmonella Typhi-
but not Salmonella Paratyphi A-positive blood cultures during a
typhoid fever epidemic after introduction of parenteral whole cell
typhoid vaccine in the national vaccination program. However, it
was a retrospective study with no control groups and the number
of Salmonella Paratyphoid A cases remained low throughout the
study. Hence there are several studies, none of which was originally
planned to answer this question, and the results remain somewhat
contentious.
As to the cross-protection against Salmonella Paratyphi B, Levine
et al. [17] re-analyzed pooled data from two  large ﬁeld trials they
had carried out in Chile: Ty21a, while conferring 58% protection
against typhoid fever, was  also found to confer 49% protection
S.H. Pakkanen et al. / Vaccine 30 (2012) 6047– 6053 6051
Fig. 4. The expression of 47, l-selectin and CLA on circulating plasmablasts (ASC) speciﬁc to (A) Salmonella Typhi- (n = 9) or (B) Salmonella Paratyphi B (n = 6) in volunteers
immunized with oral Ty21a, or speciﬁc to (C) the pathogen in patients with enteric fever (n = 4; data pooled from three patients with typhoid fever and one with paratyphoid A
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eans (±SD) of percentages of HR-positive antigen-speciﬁc ASC (IgA + IgG + IgM) am
ere  pooled are indicated under the bars.
uggested to be based on shared epitopes among the O antigens
5,17,18]. Ty21a and Salmonella Typhi both carry O-9,12, Salmonella
aratyphi A carries O-1,2,12, Salmonella Paratyphi B O-1,4,5,12,
almonella Paratyphi C O-6,7 and Salmonella Egusi O-41 antigens.
ence, both Salmonella Paratyphi A and B share the O-12 epi-
ope with Salmonella Typhi and Ty21a. Consistent with this, in the
resent study Ty21a induced a signiﬁcant cross-reactive immune
esponse to Salmonella Paratyphi A and B but not to Salmonella
aratyphi C or Salmonella Egusi (no O-antigens shared). Notably
almonella Paratyphi C shares the Vi-capsular polysaccharide with
almonella Typhi, while Ty21a lacks this structure. Presumably, Vi-
apsular polysaccharide vaccine could confer protection against
almonella Paratyphi C, which, however, represents only a rare
ause of enteric fever. The small numbers of plasmablasts reac-
ive with Salmonella Paratyphi C in six Ty21a-vaccinated volunteers
n this study are presumably due to some minor antigens present
hen whole bacteria were used as antigens.
While the present study shows a cross-reactive intestinal
umoral response, others have shown cross-reactive cell-mediated
esponses [22]: Tagliabue et al. reported a form of antibody-
ependent cellular cytotoxicity in volunteers immunized with
y21a in which IgA antibodies provide the speciﬁcity for mononu-
lear cells to kill Salmonella organisms. Post-immunization serum
amples from Ty21a recipients and mononuclear cells were able
o kill Salmonella Typhi, Salmonella Paratyphi A and B, but not
almonella Paratyphi C or Salmonella Tel Aviv, neither of which
hare O-antigen epitopes with Ty21a. Later, Nishini et al. [23] con-
ucted similar experiments and found a speciﬁc cell-mediated
mmune response not only to Salmonella Typhi but also to
almonella Paratyphi A and B in Ty21a recipients.
This study is the ﬁrst to explore cross-reactive plasmablasts
n patients with typhoid or paratyphoid fever. Both speciﬁc and
ross-reactive plasmablasts could be found in all of these patients.
hese data are in accordance with the O-/Vi-antigen properties of
hese pathogens. In patients with typhoid fever, cross-reactive plas-
ablasts were seen to Salmonella Paratyphi A, B (O-12 as shared
pitope in both strains) and C (Vi-antigen as shared epitope), and
n the patient with paratyphoid A fever, a cross-reactive response
as seen against Salmonella Typhi and Salmonella Paratyphi B (O-
2 as shared epitope), but not against Salmonella Paratyphi C (no
hared epitopes).
The  magnitude of the response in patients and vaccinees was
imilar. The timing of the sampling in vaccinees was  based on previ-
us studies showing peak values of ASC seven days after vaccinationeciﬁc plasmablasts were studied in these populations. The bars indicate arithmetic
ll antigen-speciﬁc ASC (IgA + IgG + IgM). The numbers of cases from whom the data
[18,43].  In studies on natural infections, samples are taken seven
days after onset of symptoms [36,37] as in the present study. The
long incubation time in enteric fever implies that the pathogen was
encountered several weeks earlier and hence, our timing may not
hit the peak. However, in our recent study on Salmonella gastroen-
teritis, ASC were found as long as the antigen persisted and no clear
peak was  seen [44].
The  immunoglobulin isotype distribution of the responses in the
vaccinees showed a predominance of IgA and IgM plasmablasts.
This is consistent with our previous studies showing that while
IgM response peaks on day 5, and IgG and IgA responses on day
7 [20], on day 7 both IgA and IgM predominate [20]. Notably,
the immunoglobulin isotype switch of mucosal IgA cells may take
place only after their arrival in the lamina propria, i.e. after ﬁn-
ishing the recirculation [45]. Accordingly, when assessing mucosal
immune response with the help of recirculating plasmablasts, an
analysis of all three Ig-classes should always be included, as the
circulating IgM-secreting plasmablasts may  mature into IgA pro-
ducing cells only later. This is nicely evidenced also by the fact that
basically all circulating Ty21a-speciﬁc plasmablasts, regardless of
isotype, express 47, indicating an intestinal homing of these cells
[29,30,40].
Our previous studies show that the numbers of plasmablasts
increase with increasing numbers of Ty21a vaccine doses [20]. This
increase takes place analogous to the increased protective efﬁ-
cacy against typhoid fever in ﬁeld trials with the same regimens
[46,47]. When applied to the present study, the protective efﬁ-
cacy of Ty21a would increase in the order Salmonella Paratyphi
A → Salmonella Paratyphi B → Salmonella Typhi. A lower efﬁcacy
against Salmonella Paratyphi than Salmonella Typhi appears con-
sistent with previous reports from ﬁeld trials and from travelers
[17,18]. Along with the increasing efﬁcacy against typhoid fever,
an increasing number of vaccine doses is expected to be associated
with an increase in the cross-protective efﬁcacy: even though a sig-
niﬁcant protection against typhoid fever is achieved already with
three vaccine doses, the levels of cross-protection against paraty-
phoid fever appear somewhat lower in ﬁeld trials [17], consistent
with the lower numbers of plasmablasts in this study. Adminis-
tration of four doses, as recommended in the US, could result in
a further increase in the cross-protective efﬁcacy. Even with three
doses, if the response in an individual would be too weak to con-
fer full cross-protection, the question remains whether the level
of antibodies achieved would be enough to contribute to a milder
outcome of the disease than in unvaccinated persons.
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The homing proﬁles of Salmonella Typhi- and Salmonella Paraty-
hi B-speciﬁc cross-reactive plasmablasts in the vaccinees were
imilar to one another and also similar to the pathogen-speciﬁc
lasmablasts  in enteric fever. In both groups, a pronounced tar-
eting to the intestine was  observed, as interpreted by the very
igh expression of intestinal HR, 47 and lower expression of
-selectin. Such a proﬁle appears beneﬁcial with respect to the
ntestinal transmission route both of the vaccine and of the enteric
ever. The similarities between natural infection and Ty21a in
liciting a gut-directed cross-reactive immune response against
almonella Paratyphi add to the view that Ty21a closely imitates
 natural typhoid infection.
In  conclusion, this study is the ﬁrst to show that the Ty21a vac-
ine and enteric fever both elicit cross-reactive humoral immune
esponses to both Salmonella Paratyphi A and B. The potential cross-
rotection against paratyphoid fever conferred by these immune
echanisms encourage further efﬁcacy studies. As there are no
accines against paratyphoid fever in clinical use, even a partial
rotection with a currently available vaccine would be valuable.
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